1-Isopropyl-4-(3,3,3-trifluoropropyl)benzene | 1099597-21-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-Isopropyl-4-(3,3,3-trifluoropropyl)benzene
• 英文别名: 1-propan-2-yl-4-(3,3,3-trifluoropropyl)benzene
• CAS: 1099597-21-3
• 化学式: C₁₂H₁₅F₃
• 分子量: 216.24
• InChiKey: WPPSHGCIWDODJG-UHFFFAOYSA-N

物化性质

• 沸点：
  212.1±40.0 °C(Predicted)
• 密度：
  1.053±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

文献信息

• 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists
  申请人：Hale Jeffrey John

  公开号：US20090042954A1

  公开（公告）日：2009-02-12

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P 1 /Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖I式化合物，以及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞移行，将淋巴细胞隔离在二次淋巴组织中，并增强血管完整性，具有免疫抑制，抗炎和止血活性。本发明还涉及含有这些化合物的制药组合物和治疗或预防的方法。
• Organic electroluminescent materials and devices
  申请人：Universal Display Corporation

  公开号：US11018309B2

  公开（公告）日：2021-05-25

  This invention discloses phosphorescent metal complexes with novel ligand structures of Formula I: wherein X, Z1, Z2, Z3, rings A and C, RA, RB, RC, and ligand LA are as described herein. These complexes are used as emitters in phosphorescent OLEDs.

  本发明公开了具有式 I 新型配体结构的磷光金属配合物： 其中 X、Z1、Z2、Z3、环 A 和 C、RA、RB、RC 和配体 LA 如本文所述。这些复合物可用作磷光 OLED 的发光体。
• PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE
  申请人：Mitsui Chemicals Agro, Inc.

  公开号：EP3636636B1

  公开（公告）日：2022-07-06
• MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE
  申请人：Canget BioTekpharma

  公开号：US20200231596A1

  公开（公告）日：2020-07-23

  Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.
• US7659294B2
  申请人：——

  公开号：US7659294B2

  公开（公告）日：2010-02-09